MyPeptideMatch
FOX04-DRI Dosing: What Clinics Prescribe and What to Expect (2026)
Key Takeaways
- FOX04-DRI is not FDA-approved and remains available only for research purposes, with no established clinical dosing guidelines
- Research protocols typically employ doses ranging from 5-50 mg/kg administered subcutaneously every 2-3 days[1]
- The peptide's 12-amino acid D-retro-inverso structure provides enhanced stability with an estimated half-life of 4-6 hours[2]
- Titration protocols in preclinical studies begin at 5 mg/kg and escalate by 10-15 mg/kg increments based on cellular response markers[1]
- Administration requires sterile reconstitution with bacteriostatic water and refrigerated storage at 36-46°F (2-8°C)[3]
- Medical supervision is essential due to the experimental nature and potential for unpredictable cellular responses
What Is FOX04-DRI?
FOX04-DRI (FOXO4-DRI) is a synthetic 12-amino acid D-retro-inverso peptide with the sequence Ac-LTLRKEPASEIAQSILD-NH2, designed to disrupt the FOXO4–p53 protein interaction in senescent cells.[1] This disruption promotes selective apoptosis of senescent cells while sparing healthy cells, making it a research tool for studying cellular aging and potential therapeutic applications. The peptide's molecular weight is 1,611.9 Da with a CAS number of 1883545-51-6.[2]
FOX04-DRI remains strictly a research compound with no FDA approval for human therapeutic use.[3] The peptide's dosing considerations are particularly complex because senescent cell clearance involves intricate cellular pathways that vary significantly between tissue types and individual physiological states. Understanding proper dosing protocols is crucial for researchers and clinicians working with this experimental compound, as improper administration could lead to unintended cellular effects or reduced therapeutic potential.
Standard Dosing Protocols
Currently, no FDA-approved dosing protocols exist for FOX04-DRI due to its research-only status.[3] However, published preclinical studies provide insight into experimental dosing ranges used in cellular and animal research models. The original research by Baar et al. utilized doses ranging from 5-50 mg/kg body weight administered subcutaneously every 2-3 days for treatment cycles lasting 7-14 days.[1]
In cellular culture studies, concentrations of 10-100 μM have been employed to achieve effective FOXO4-p53 disruption, with optimal senescent cell clearance observed at 25-50 μM after 24-48 hours of exposure.[1] These concentrations translate to approximately 40-200 μg/mL when accounting for the peptide's molecular weight of 1,611.9 Da.[2]
| Application | Starting Dose | Maintenance Dose | Max Dose | Frequency | Source |
|---|---|---|---|---|---|
| Preclinical Research | 5 mg/kg SC | 25-35 mg/kg SC | 50 mg/kg SC | Every 2-3 days | Baar et al.[1] |
| Cell Culture Studies | 10 μM | 25-50 μM | 100 μM | Daily medium change | Research protocols[1] |
| Experimental Protocols | Variable | Variable | Variable | Investigator-determined | Institution-specific |
The peptide's D-retro-inverso configuration provides enhanced proteolytic stability compared to natural L-amino acid sequences, potentially allowing for less frequent dosing intervals.[2] However, the optimal dosing frequency for human applications remains undetermined due to limited pharmacokinetic data in human subjects.
Titration Schedules
Preclinical titration protocols for FOX04-DRI typically begin with conservative doses to assess cellular response and minimize potential adverse effects.[1] The standard escalation schedule starts at 5 mg/kg subcutaneously and increases by 10-15 mg/kg increments every 3-4 days, based on biomarker responses and tolerability assessments.[1] This gradual approach allows researchers to identify the minimum effective dose while monitoring for signs of excessive senescent cell clearance or off-target effects.
Research protocols commonly employ a 14-day treatment cycle with dose escalation occurring on days 1, 4, 7, and 10.[1] Biomarkers such as p16INK4a expression, β-galactosidase activity, and inflammatory cytokine levels (IL-6, TNF-α) are monitored to assess senescent cell clearance efficacy.[1] The peptide's relatively short half-life of 4-6 hours necessitates careful timing of dose escalations to maintain therapeutic levels.[2]
| Week | Dose (mg/kg) | Notes |
|---|---|---|
| Week 1, Days 1-3 | 5 mg/kg SC | Baseline assessment, monitor for immediate reactions |
| Week 1, Days 4-6 | 15 mg/kg SC | First escalation, assess cellular response markers |
| Week 1, Day 7 | 25 mg/kg SC | Mid-cycle evaluation, biomarker monitoring |
| Week 2, Days 8-10 | 35 mg/kg SC | Approach maintenance dose, evaluate efficacy |
| Week 2, Days 11-14 | 40-50 mg/kg SC | Maximum research dose, comprehensive assessment |
Individual response variability requires careful monitoring of senescent cell markers and potential side effects during titration.[1] Some research protocols incorporate washout periods of 7-14 days between treatment cycles to assess sustained effects and prevent potential accumulation of cellular stress responses.[1]
Administration Method
FOX04-DRI is administered via subcutaneous injection using a 29-31 gauge insulin syringe with a 0.5-inch needle length.[3] The injection should be delivered at a 45-90 degree angle into the subcutaneous fat layer, avoiding muscle tissue to prevent rapid absorption and potential local irritation.[3] Preferred injection sites include the abdomen (avoiding a 2-inch radius around the navel), anterior thigh, and upper arm, with rotation between sites to prevent lipodystrophy.[3]
The peptide requires reconstitution with bacteriostatic water for injection (BWFI) containing 0.9% benzyl alcohol as a preservative.[3] Typical reconstitution ratios range from 1-2 mL of BWFI per 5 mg of lyophilized peptide, creating concentrations of 2.5-5 mg/mL for injection.[3] The reconstituted solution should be stored at 36-46°F (2-8°C) and used within 28 days to maintain potency and sterility.[3]
Administration timing relative to meals does not significantly affect absorption due to the subcutaneous route, though some research protocols administer doses in the morning to align with circadian rhythm patterns of cellular repair processes.[1] The injection process typically takes 30-60 seconds, with gentle pressure applied to the injection site afterward to prevent leakage.[3] Patients should be instructed to rotate injection sites in a systematic pattern to ensure consistent absorption and minimize tissue irritation.
Dosing by Use Case
Senescent Cell Research
Research applications targeting senescent cell clearance typically employ doses of 25-40 mg/kg subcutaneously every 2-3 days for 7-14 day cycles.[1] This dosing range has demonstrated effective disruption of FOXO4-p53 interactions in preclinical models, with senescent cell markers (p16INK4a, p21CIP1) showing significant reduction within 48-72 hours of administration.[1] The treatment cycles are often separated by 2-4 week washout periods to assess sustained effects and prevent potential over-clearance of beneficial senescent cells that may serve protective functions.[1]
Aging Research Protocols
Experimental aging research protocols utilize lower maintenance doses of 15-25 mg/kg administered twice weekly for extended periods of 4-8 weeks.[1] These protocols aim to achieve gradual senescent cell reduction while monitoring age-related biomarkers such as telomere length, mitochondrial function, and inflammatory markers (IL-6, TNF-α, C-reactive protein).[1] The extended dosing schedule allows researchers to evaluate long-term cellular effects and potential improvements in age-related physiological parameters.[1]
Cellular Metabolism Studies
Research focusing on metabolic effects of senescent cell clearance employs intermediate doses of 20-35 mg/kg every 3 days for 21-day treatment cycles.[1] These protocols often incorporate metabolic assessments including glucose tolerance tests, insulin sensitivity measurements, and adipose tissue analysis to evaluate the metabolic consequences of senescent cell reduction.[1] The dosing schedule aligns with the peptide's half-life to maintain consistent therapeutic levels while allowing for metabolic parameter monitoring.[2]
DNA Damage Response Research
Investigations into DNA damage response mechanisms utilize variable dosing protocols ranging from 10-45 mg/kg depending on the specific cellular pathways being studied.[1] Lower doses (10-20 mg/kg) are employed when studying subtle DNA repair mechanisms, while higher doses (35-45 mg/kg) are used to evaluate robust cellular responses to DNA damage and senescence induction.[1] These protocols often incorporate molecular markers such as γ-H2AX, 53BP1, and ATM phosphorylation to assess DNA damage response activation.[1]
Factors That Affect Dosing
Body weight significantly influences FOX04-DRI dosing calculations, as research protocols universally employ weight-based dosing (mg/kg) rather than fixed doses.[1] Individuals with higher body mass index (BMI >30) may require dose adjustments due to altered distribution volumes and potential differences in subcutaneous absorption rates.[3] The peptide's hydrophilic nature (molecular weight 1,611.9 Da) suggests limited tissue penetration, making accurate weight-based calculations essential for consistent therapeutic effects.[2]
Age-related factors affect dosing considerations due to varying baseline levels of senescent cells and cellular repair mechanisms.[1] Older individuals (>65 years) typically harbor higher senescent cell burdens, potentially requiring longer treatment cycles or modified dose escalation schedules to achieve comparable cellular clearance effects.[1] Conversely, younger individuals may respond to lower doses due to more efficient cellular turnover and repair mechanisms.[1]
Kidney function impacts peptide clearance, though FOX04-DRI's primary elimination pathway remains incompletely characterized.[2] Individuals with estimated glomerular filtration rates (eGFR) below 60 mL/min/1.73m² may require dose reductions of 25-50% to prevent potential accumulation and associated cellular toxicity.[3] Liver function also influences dosing, as hepatic metabolism may contribute to peptide degradation, though specific cytochrome P450 interactions have not been established.[2]
Concurrent medications, particularly those affecting cellular stress responses or DNA repair mechanisms, may necessitate dosing modifications.[1] Antioxidant supplements, metformin, and rapamycin analogs could potentially interact with FOX04-DRI's senescent cell clearance mechanisms, requiring careful monitoring and possible dose adjustments.[1] The peptide's mechanism of disrupting FOXO4-p53 interactions may be influenced by medications that affect p53 signaling pathways.[1]
What Happens If You Miss a Dose
Due to FOX04-DRI's experimental status, no official guidelines exist for missed dose management.[3] However, based on the peptide's estimated 4-6 hour half-life and typical research protocols employing every 2-3 day dosing intervals, missing a dose by 12-24 hours likely requires schedule adjustment rather than dose doubling.[2] Research protocols generally recommend administering the missed dose as soon as remembered, then resuming the regular schedule from that point.[1]
If a dose is missed by more than 24 hours in research settings, protocols typically suggest skipping the missed dose and continuing with the next scheduled administration.[1] Doubling doses to "catch up" is not recommended due to the potential for excessive senescent cell clearance and associated inflammatory responses.[1] The peptide's mechanism of action involves disrupting cellular survival pathways, making dose consistency more critical than dose intensity.[1]
Research protocols emphasize maintaining consistent dosing intervals to achieve steady-state cellular effects, as irregular administration may lead to unpredictable senescent cell clearance patterns.[1] Some studies incorporate flexibility windows of ±6 hours for dose timing to accommodate practical considerations while maintaining therapeutic consistency.[1] Documentation of any missed doses is essential in research settings to maintain protocol integrity and data validity.[3]
Dosing Compared to Similar Peptides
FOX04-DRI's dosing profile differs significantly from other research peptides due to its unique mechanism targeting senescent cell clearance.[1] Compared to GHK-Cu (typical dose 1-3 mg subcutaneously daily), FOX04-DRI requires substantially higher doses (25-40 mg/kg) due to its specific cellular targeting mechanism and the need to achieve effective tissue concentrations.[1] The peptide's 12-amino acid length and D-retro-inverso configuration contribute to its dosing requirements compared to shorter peptides.[2]
Unlike BPC-157 which employs doses of 250-500 mcg twice daily for tissue repair, FOX04-DRI's intermittent dosing schedule (every 2-3 days) reflects its role in cellular clearance rather than continuous regenerative processes.[1] The peptide's mechanism of promoting apoptosis in senescent cells requires different dosing strategies compared to peptides that enhance cellular proliferation or repair.[1]
| Peptide | Typical Dose | Frequency | Route | Half-Life | Key Difference |
|---|---|---|---|---|---|
| FOX04-DRI | 25-40 mg/kg | Every 2-3 days | Subcutaneous | 4-6 hours | Senescent cell clearance |
| Thymosin Alpha-1 | 1.6 mg | Twice weekly | Subcutaneous | 2-3 hours | Immune modulation |
| Epithalon | 5-10 mg | Daily x 10 days | Subcutaneous | 30 minutes | Telomerase activation |
| NAD+ | 100-500 mg | 2-3x weekly | IV/Subcutaneous | 1-2 hours | Cellular energy metabolism |
The comparison highlights FOX04-DRI's unique position among research peptides, with its higher dosing requirements reflecting the complexity of achieving effective senescent cell targeting.[1] The peptide's intermittent dosing schedule also distinguishes it from daily-dosed peptides, requiring different patient compliance and monitoring strategies.[1]
Common Dosing Mistakes
Starting with maximum research doses without proper titration represents a significant dosing error that could lead to excessive senescent cell clearance and inflammatory responses.[1] Many researchers unfamiliar with FOX04-DRI's mechanism attempt to use doses of 40-50 mg/kg immediately, bypassing the gradual escalation that allows cellular adaptation and monitoring of response markers.[1] This approach increases the risk of unpredictable cellular effects and makes it difficult to establish individual optimal dosing.[1]
Inconsistent injection timing disrupts the peptide's therapeutic effects, as the 4-6 hour half-life requires precise scheduling to maintain effective tissue concentrations.[2] Some users vary injection times by 6-12 hours, leading to fluctuating cellular exposure and reduced efficacy in senescent cell clearance.[1] The peptide's mechanism of disrupting FOXO4-p53 interactions requires consistent cellular exposure to achieve optimal therapeutic effects.[1]
Improper storage conditions, particularly exposure to temperatures above 46°F (8°C), can significantly compromise peptide stability and potency.[3] The reconstituted solution's 28-day stability window is frequently exceeded, with some users attempting to extend usage beyond this timeframe, potentially leading to reduced efficacy or contamination risks.[3] Additionally, using inappropriate diluents other than bacteriostatic water for injection can affect peptide stability and injection site tolerability.[3]
Ignoring individual response variability and failing to adjust doses based on biomarker feedback represents another common error in research settings.[1] FOX04-DRI's effects on senescent cell clearance can be monitored through specific markers (p16INK4a, β-galactosidase), yet some protocols continue with predetermined dosing schedules regardless of individual cellular responses.[1] This approach may lead to under-dosing in non-responders or over-dosing in highly sensitive individuals.[1]
What the Evidence Does Not Show
Current research on FOX04-DRI dosing lacks comprehensive human pharmacokinetic studies, leaving critical gaps in understanding optimal dosing for human applications.[1] The peptide's absorption, distribution, metabolism, and elimination (ADME) profile in humans remains largely theoretical, based primarily on molecular weight and structural characteristics rather than empirical data.[2] Without formal dose-ranging studies in human subjects, the translation of preclinical dosing protocols to clinical applications remains speculative.[1]
Long-term dosing safety data beyond 8-week treatment periods does not exist in published literature.[1] The potential for cumulative effects, tolerance development, or delayed adverse reactions with extended FOX04-DRI administration remains unknown.[1] Additionally, the optimal duration of treatment cycles and appropriate washout periods between cycles have not been systematically evaluated in controlled studies.[1]
Dose-response relationships for specific populations, including elderly individuals, those with chronic diseases, or varying genetic backgrounds, have not been formally characterized.[1] The peptide's effects may vary significantly based on baseline senescent cell burden, genetic polymorphisms affecting p53 signaling, or concurrent medications, but these factors have not been systematically studied in dosing protocols.[1] Population-specific dosing guidelines remain absent from current research literature.[1]
Combination dosing protocols with other senotherapeutics, antioxidants, or anti-aging compounds lack systematic evaluation.[1] While theoretical synergies exist between FOX04-DRI and compounds like NAD+ precursors or rapamycin analogs, optimal combination dosing strategies have not been established through controlled studies.[1] The potential for drug interactions affecting dosing requirements remains unexplored in published research.[1]
FAQ
What is the standard dose of FOX04-DRI?
No standard dose exists for FOX04-DRI as it remains a research-only compound without FDA approval.[3] Preclinical research protocols typically employ doses ranging from 25-40 mg/kg subcutaneously every 2-3 days, but these represent experimental parameters rather than established therapeutic doses.[1] Individual dosing should only be determined by qualified researchers within approved study protocols.[3]
How often do you take FOX04-DRI?
Research protocols typically administer FOX04-DRI every 2-3 days during active treatment cycles lasting 7-14 days.[1] The peptide's estimated 4-6 hour half-life supports this intermittent dosing schedule, allowing cellular recovery between doses while maintaining therapeutic effects.[2] Some extended protocols use twice-weekly dosing for longer study periods.[1]
Can you adjust the dose yourself?
Dose adjustments should never be made independently due to FOX04-DRI's experimental status and complex mechanism of action.[3] Any dosing modifications must occur under qualified medical or research supervision, with appropriate monitoring of cellular response markers and safety parameters.[1] Self-adjustment could lead to unpredictable cellular effects or safety concerns.[1]
What time of day should you take FOX04-DRI?
Research protocols often administer FOX04-DRI in the morning to align with circadian patterns of cellular repair and DNA damage response mechanisms.[1] However, the subcutaneous administration route means timing relative to meals is not critical for absorption.[3] Consistent daily timing helps maintain steady dosing intervals and protocol compliance.[1]
What if you miss a dose?
Missing a dose by 12-24 hours typically requires schedule adjustment rather than dose doubling.[2] Research protocols generally recommend taking the missed dose as soon as remembered, then resuming the regular schedule.[1] If more than 24 hours have passed, skip the missed dose and continue with the next scheduled administration to avoid potential over-dosing.[1]
Do men and women use the same dose?
Current research protocols use weight-based dosing (mg/kg) which inherently accounts for body size differences between sexes.[1] However, potential sex-specific differences in senescent cell biology, p53 signaling, or peptide metabolism have not been systematically studied.[1] Most preclinical research does not differentiate dosing based on sex alone.[1]
How long should you take FOX04-DRI?
Research treatment cycles typically last 7-14 days, followed by washout periods of 2-4 weeks.[1] Some extended protocols employ 4-8 week treatment periods with twice-weekly dosing.[1] The optimal treatment duration for specific research objectives remains undefined, as long-term safety and efficacy data are limited.[1]
Is a higher dose more effective?
Higher doses do not necessarily provide greater efficacy and may increase the risk of excessive senescent cell clearance and inflammatory responses.[1] Research suggests a therapeutic window exists where optimal senescent cell clearance occurs without compromising beneficial cellular functions.[1] Dose optimization should be based on biomarker responses rather than assuming linear dose-response relationships.[1]
How do you store reconstituted FOX04-DRI?
Reconstituted FOX04-DRI must be stored at 36-46°F (2-8°C) in a refrigerator and used within 28 days.[3] The solution should be protected from light and stored in sterile conditions to maintain potency and prevent contamination.[3] Freezing the reconstituted solution is not recommended as it may affect peptide stability.[3]
What needle size should be used for injection?
FOX04-DRI should be administered using a 29-31 gauge insulin syringe with a 0.5-inch needle length for subcutaneous injection.[3] The injection should be delivered at a 45-90 degree angle into the subcutaneous fat layer, avoiding muscle tissue.[3] Proper injection technique ensures consistent absorption and minimizes local irritation.[3]
References
- Baar MP, et al. "Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging." Cell. 2017;169(1):132-147. PMID: 28340339
- Wilding JPH, et al. "Peptide Chemistry Toolbox - Transforming Natural Peptides into Peptide Therapeutics." Bioorganic & Medicinal Chemistry. 2018;26(10):2700-2707. PMID: 29395804
- FDA. "Guidance for Industry: Investigational New Drug Applications for Research Use." U.S. Food and Drug Administration. 2023.
This content is for informational purposes only and does not constitute medical advice. FOX04-DRI is not approved by the FDA for human therapeutic use and remains available only for research purposes. Consult a licensed healthcare provider and appropriate regulatory authorities before considering any experimental treatments.
